Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rupatadine in Nonalcoholic Fatty Liver Disease
NCT07900100Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rupatadine in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Tanta University. Primary endpoint: Change in the degree of steatosis at 3 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
rupatadine
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07900100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900100.